Get Free Trial
News & Analysis
On The Fly
About The Fly
Instant updates and real-time market news.
Genpact files to sell 10M shares of common stock for holders
J.P. Morgan is acting as the sole underwriter for the offering.
H-1B visa restrictions would be positive for Genpact, says Piper Jaffray
Piper Jaffray analyst George Tong says he's incrementally more positive on the growth prospects for Genpact following a policy analysis of the Trump administration's stance on immigration reform and H-1B visas. A tightening of H-1B visa quotas will constrain the supply of skilled labor and drive upward pressure on wages, prompting employers to consider business process outsourcing as an alternative to organic hiring, Tong tells investors in a research note. Further, the analyst expects Genpact's competitors in IT outsourcing to be disproportionately harmed by restrictions in the H-1B visa program. Tong has an Overweight rating on Genpact with a $29 price target.
Genpact initiated with a Neutral at Wedbush
Wedbush analyst Moshe Katri initiated Genpact with a Neutral and a $33 price target.
Genpact could be $40 stock by late 2018, says Baird
Baird analyst David Koning views Genpact as a very good idea in a market where good ideas are difficult to find. The analyst sees the shares as compelling despite headwinds in foreign exchange. He said its valuation is below peers and the company is showing core growth stability. Koning said it is possible the stock could reach $40 by the end of 2018. Koning reiterated his Outperform rating and $34 price target on Genpact.
Genpact price target raised to $36 from $32 at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph Foresi raised his price target for Genpact Limited to $36 following the company's Q3 results and reiterates an Overweight rating on the shares.
TODAY'S FREE FLY STORIES